Definitive Contract 75A50124C00052
Award Date
9/30/24
Potential Completion Date
3/31/32
Potential Value
$330M
Awardee
4J Therapeutics Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a Firm Fixed Price contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janus-I Science Inc., a self-certified small disadvantaged business. The contract, valued at $710,619.00, is for Direct RNA Sequencing of Emerging Respiratory Agents and Host Response, under the JANUS-I program. This contract was awarded on April 15, 2019, with a completion date of October 14, 2020. It was not set aside for any...
This is a $918,380,272.80 definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Phlow Corp, a for-profit pharmaceutical manufacturer, to provide U.S.-based advanced manufacturing of COVID-19 essential medicines and responses to future threats. The contract has a 10-year period of performance ending in May 2030 and uses a cost-plus-fixed-fee pricing structure. The award is funded under ASPR's...
This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $63,239,785.00 definitive contract to Arcturus Therapeutics, Inc. for the procurement of a pandemic influenza vaccine (PandFlu) and a quadrivalent seasonal influenza vaccine (QsFlu). This contract is not a set-aside and supports the Arcturus self-amplifying mRNA-based vaccine platform for rapid pandemic influenza response, a key priority under ASPR's Biomedical...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...
The Department of Health and Human Services' Biomedical Advanced Research and Development Authority awarded a $269,952,453 firm fixed price definitive contract to Global Health Investment Corporation, a nonprofit organization. This contract establishes a public-private partnership through BARDA's other transaction authority to address gaps in pandemic preparedness and response. Specifically, the partnership will foster and accelerate medical countermeasure development using strategic venture...
This is a $749,999.01 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Red Queen Therapeutics Inc., a self-certified small disadvantaged business. The contract is for research and development of a rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections. This contract is not set aside and has an ultimate completion date of...